BI Asset Management Fondsmaeglerselskab A S Has $20.08 Million Stock Position in Boston Scientific Corporation $BSX

BI Asset Management Fondsmaeglerselskab A S lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 13.9% during the 3rd quarter, Holdings Channel reports. The firm owned 205,680 shares of the medical equipment provider’s stock after acquiring an additional 25,136 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Boston Scientific were worth $20,081,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Steph & Co. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at about $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific during the third quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter valued at approximately $26,000. United Community Bank increased its stake in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares in the last quarter. Finally, Kilter Group LLC acquired a new stake in Boston Scientific in the second quarter worth $30,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BSX. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, January 21st. UBS Group reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Stifel Nicolaus set a $110.00 price target on Boston Scientific in a research report on Wednesday. Canaccord Genuity Group cut their price objective on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Finally, Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $121.84.

Boston Scientific Trading Down 17.6%

NYSE BSX opened at $75.50 on Thursday. Boston Scientific Corporation has a 52 week low of $75.00 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock’s 50 day moving average price is $94.37 and its two-hundred day moving average price is $99.13. The stock has a market capitalization of $111.92 billion, a price-to-earnings ratio of 40.37, a PEG ratio of 1.63 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the firm posted $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat on both EPS and revenue; revenue grew ~15.9% year-over-year, and margins improved — the underlying quarter was strong, showing continued organic growth across several franchises. Boston Scientific announces results for fourth quarter and full year 2025
• Neutral Sentiment: Analyst coverage and the company’s earnings materials/earnings call provide detail for valuation and segment trends — useful for investors who want to dig into segment-level drivers and management’s assumptions. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Management’s FY‑2026 guidance was modestly below or roughly in line with Street expectations (FY EPS range and revenue range came in light enough to reset growth assumptions), and Q1 guidance was cautious — that outlook is the main driver of the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology (one of Boston Scientific’s higher-growth, higher-profile segments) underperformed vs. expectations, which worried investors about near-term growth momentum in a key franchise. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Unusually large put-option activity and heavy trading signaled short-term bearish positioning and hedging, amplifying downside pressure. BSX Earnings: Boston Scientific Stock Plunges on Weak Guidance
• Negative Sentiment: CEO insider selling (large block disclosed) adds to near-term negative sentiment even though insider transactions can be for many reasons. Insider sale SEC filing

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.